Cargando…

MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice

SIMPLE SUMMARY: We deeply characterized a frequently used mouse model of prostate cancer and found cellular and molecular regulators of resistance against antihormonal treatment, such as basal cell function and MALAT1 gene fusions. As these mechanisms also occur in human disease, our findings highli...

Descripción completa

Detalles Bibliográficos
Autores principales: Marhold, Maximilian, Udovica, Simon, Topakian, Thais, Horak, Peter, Horvat, Reinhard, Tomasich, Erwin, Heller, Gerwin, Krainer, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833778/
https://www.ncbi.nlm.nih.gov/pubmed/35159020
http://dx.doi.org/10.3390/cancers14030749
_version_ 1784649028008411136
author Marhold, Maximilian
Udovica, Simon
Topakian, Thais
Horak, Peter
Horvat, Reinhard
Tomasich, Erwin
Heller, Gerwin
Krainer, Michael
author_facet Marhold, Maximilian
Udovica, Simon
Topakian, Thais
Horak, Peter
Horvat, Reinhard
Tomasich, Erwin
Heller, Gerwin
Krainer, Michael
author_sort Marhold, Maximilian
collection PubMed
description SIMPLE SUMMARY: We deeply characterized a frequently used mouse model of prostate cancer and found cellular and molecular regulators of resistance against antihormonal treatment, such as basal cell function and MALAT1 gene fusions. As these mechanisms also occur in human disease, our findings highlight the importance of this model for human cancer and may be helpful for future research focusing on overcoming antihormonal treatment resistance. ABSTRACT: Targeting testosterone signaling through androgen deprivation therapy (ADT) or antiandrogen treatment is the standard of care for advanced prostate cancer (PCa). Although the large majority of patients initially respond to ADT and/or androgen receptor (AR) blockade, most patients suffering from advanced PCa will experience disease progression. We sought to investigate drivers of primary resistance against antiandrogen treatment in the TRAMP mouse model, an SV-40 t-antigen driven model exhibiting aggressive variants of prostate cancer, castration resistance, and neuroendocrine differentiation upon antihormonal treatment. We isolated primary tumor cell suspensions from adult male TRAMP mice and subjected them to organoid culture. Basal and non-basal cell populations were characterized by RNA sequencing, Western blotting, and quantitative real-time PCR. Furthermore, effects of androgen withdrawal and enzalutamide treatment were studied. Basal and luminal TRAMP cells exhibited distinct molecular signatures and gave rise to organoids with distinct phenotypes. TRAMP cells exhibited primary resistance against antiandrogen treatment. This was more pronounced in basal cell-derived TRAMP organoids when compared to luminal cell-derived organoids. Furthermore, we found MALAT1 gene fusions to be drivers of antiandrogen resistance in TRAMP mice through regulation of AR. Summarizing, TRAMP tumor cells exhibited primary resistance towards androgen inhibition enhanced through basal cell function and MALAT1 gene fusions.
format Online
Article
Text
id pubmed-8833778
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88337782022-02-12 MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice Marhold, Maximilian Udovica, Simon Topakian, Thais Horak, Peter Horvat, Reinhard Tomasich, Erwin Heller, Gerwin Krainer, Michael Cancers (Basel) Article SIMPLE SUMMARY: We deeply characterized a frequently used mouse model of prostate cancer and found cellular and molecular regulators of resistance against antihormonal treatment, such as basal cell function and MALAT1 gene fusions. As these mechanisms also occur in human disease, our findings highlight the importance of this model for human cancer and may be helpful for future research focusing on overcoming antihormonal treatment resistance. ABSTRACT: Targeting testosterone signaling through androgen deprivation therapy (ADT) or antiandrogen treatment is the standard of care for advanced prostate cancer (PCa). Although the large majority of patients initially respond to ADT and/or androgen receptor (AR) blockade, most patients suffering from advanced PCa will experience disease progression. We sought to investigate drivers of primary resistance against antiandrogen treatment in the TRAMP mouse model, an SV-40 t-antigen driven model exhibiting aggressive variants of prostate cancer, castration resistance, and neuroendocrine differentiation upon antihormonal treatment. We isolated primary tumor cell suspensions from adult male TRAMP mice and subjected them to organoid culture. Basal and non-basal cell populations were characterized by RNA sequencing, Western blotting, and quantitative real-time PCR. Furthermore, effects of androgen withdrawal and enzalutamide treatment were studied. Basal and luminal TRAMP cells exhibited distinct molecular signatures and gave rise to organoids with distinct phenotypes. TRAMP cells exhibited primary resistance against antiandrogen treatment. This was more pronounced in basal cell-derived TRAMP organoids when compared to luminal cell-derived organoids. Furthermore, we found MALAT1 gene fusions to be drivers of antiandrogen resistance in TRAMP mice through regulation of AR. Summarizing, TRAMP tumor cells exhibited primary resistance towards androgen inhibition enhanced through basal cell function and MALAT1 gene fusions. MDPI 2022-01-31 /pmc/articles/PMC8833778/ /pubmed/35159020 http://dx.doi.org/10.3390/cancers14030749 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Marhold, Maximilian
Udovica, Simon
Topakian, Thais
Horak, Peter
Horvat, Reinhard
Tomasich, Erwin
Heller, Gerwin
Krainer, Michael
MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice
title MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice
title_full MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice
title_fullStr MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice
title_full_unstemmed MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice
title_short MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice
title_sort malat1 fusions and basal cells contribute to primary resistance against androgen receptor inhibition in tramp mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833778/
https://www.ncbi.nlm.nih.gov/pubmed/35159020
http://dx.doi.org/10.3390/cancers14030749
work_keys_str_mv AT marholdmaximilian malat1fusionsandbasalcellscontributetoprimaryresistanceagainstandrogenreceptorinhibitionintrampmice
AT udovicasimon malat1fusionsandbasalcellscontributetoprimaryresistanceagainstandrogenreceptorinhibitionintrampmice
AT topakianthais malat1fusionsandbasalcellscontributetoprimaryresistanceagainstandrogenreceptorinhibitionintrampmice
AT horakpeter malat1fusionsandbasalcellscontributetoprimaryresistanceagainstandrogenreceptorinhibitionintrampmice
AT horvatreinhard malat1fusionsandbasalcellscontributetoprimaryresistanceagainstandrogenreceptorinhibitionintrampmice
AT tomasicherwin malat1fusionsandbasalcellscontributetoprimaryresistanceagainstandrogenreceptorinhibitionintrampmice
AT hellergerwin malat1fusionsandbasalcellscontributetoprimaryresistanceagainstandrogenreceptorinhibitionintrampmice
AT krainermichael malat1fusionsandbasalcellscontributetoprimaryresistanceagainstandrogenreceptorinhibitionintrampmice